Psilocybin and Psilocyn

Phase 2Small molecule

FFederal University of Latin American Integration

Psilocybin and Psilocyn is one of 2 small molecule programs targeting Refractory Depression. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory DepressionRecruiting

Refractory DepressionPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Refractory Depression

#DrugCompanyPhaseTrials

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 2

Psilocybin and Psilocyn

FFederal University of Latin American Integration

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Refractory Depression

NCT06898606

Clinical

Trials by Indication[1]

Refractory Depression1 trial

Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression: a Phase 2a Pilot Randomized Clinical Trial (COGUNILA)

Recruiting·FFederal University of Latin American Integration·Phase 1/2·NCT06898606·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Psilocybin and Psilocyn. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psilocybin and Psilocyn compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psilocybin and Psilocyn. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal University of Latin American Integration company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFederal University of Latin American Integration

Psilocybin and Psilocyn

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Refractory Depression1 trial

References

Drug Info

Quick Facts

Related News